본문 바로가기
KERD
논문KCI 등재후보

Update of the clinical guideline for hypertension diagnosis and treatment in Iran

Bagherikholenjani Fahimeh|Shahidi Shahla|Khosravi Alireza|Mansouri Asieh|Ashoorion Vahid|Sarrafzadegan Nizal
대한고혈압학회 (The Korean Society of Hypertension)|2024.01|Clinical Hypertension|제30권 |pp. 13-13|DOI 10.1186/s40885-024-00269-6

3

조회

0

다운로드

0

인용

0

참고문헌

키워드

HypertensionTreatmentDiagnosisBlood PressureClinical practice GuidelineUpdating

초록

This article introduces the updated version of the Iranian guideline for the diagnosis and treatment of hypertension in adults. The initial version of the national guideline was developed in 2011 and updated in 2014. Among the reasons necessitating the update of this guideline were the passage of time, the incompleteness of the scopes, the limitation of the target group, and more important is the request of the ministry of health in Iran.The members of the guideline updating group, after reviewing the original version and the new evidence, prepared 10 clinical questions regarding hypertension, and based on the evidence found from the latest scientific documents, provided recommendations or suggestions to answer these questions.According to the updated guideline, the threshold for office prehypertension diagnosis should be considered the systolic blood pressure (SBP) of 130-139 mmHg and/or the diastolic blood pressure (DBP) of 80-89 mmHg, and in adults under 75 years of age without comorbidities, the threshold for office hypertension diagnosis should be SBP ≥ 140 mmHg and or DBP ≥ 90 mmHg.The goal of treatment in adults who lack comorbidities and risk factors is SBP < 140 mmHg and DBP < 90 mmHg. The first-line treatment recommended in people with prehypertension is lifestyle modification, while for those with hypertension, pharmacotherapy along with lifestyle modification. The threshold to start drug therapy is determined at SBP ≥ 140 mmHg and or DBP ≥ 90 mmHg, and the first-line treatment is considered a drug or a combined pill of antihypertensive drugs, including ACEIs, ARBs, thiazide and thiazide-like agents, or CCBs.At the beginning of the pharmacotherapy, the Guideline Updating Group members suggested studying serum electrolytes, creatinine, lipid profile, fasting sugar, urinalysis, and an electrocardiogram. Regarding the visit intervals, monthly visits are suggested at the beginning of the treatment or in case of any change in the type or dosage of the drug until achieving the treatment goal, followed by every 3-to-6-month visits. Moreover, to reduce further complications, it was suggested that healthcare unit employees use telehealth strategies.In this guideline, specific recommendations and suggestions have been presented for adults and subgroups like older people or those with cardiovascular disease, diabetes mellitus, chronic kidney disease, and COVID-19.

Abstract

Background This article introduces the updated version of the Iranian guideline for the diagnosis and treatment of hypertension in adults. The initial version of the national guideline was developed in 2011 and updated in 2014. Among the reasons necessitating the update of this guideline were the passage of time, the incompleteness of the scopes, the limitation of the target group, and more important is the request of the ministry of health in Iran. Method The members of the guideline updating group, after reviewing the original version and the new evidence, prepared 10 clinical questions regarding hypertension, and based on the evidence found from the latest scientifc documents, provided recommendations or suggestions to answer these questions. Result According to the updated guideline, the threshold for ofce prehypertension diagnosis should be considered the systolic blood pressure (SBP) of 130-139 mmHg and/or the diastolic blood pressure (DBP) of 80-89 mmHg, and in adults under 75 years of age without comorbidities, the threshold for ofce hypertension diagnosis should be SBP≥140 mmHg and or DBP≥90 mmHg. The goal of treatment in adults who lack comorbidities and risk factors is SBP<140 mmHg and DBP<90 mmHg. The frst-line treatment recommended in people with prehypertension is lifestyle modifcation, while for those with hypertension, pharmacotherapy along with lifestyle modifcation. The threshold to start drug therapy is determined at SBP≥140 mmHg and or DBP≥90 mmHg, and the frst-line treatment is considered a drug or a combined pill of antihypertensive drugs, including ACEIs, ARBs, thiazide and thiazide-like agents, or CCBs. At the beginning of the pharmacotherapy, the Guideline Updating Group members suggested studying serum electrolytes, creatinine, lipid profle, fasting sugar, urinalysis, and an electrocardiogram. Regarding the visit intervals, monthly visits are suggested at the beginning of the treatment or in case of any change in the type or dosage of the drug until achieving the treatment goal, followed by every 3-to-6-month visits. Moreover, to reduce further complications, it was suggested that healthcare unit employees use telehealth strategies. Conclusions In this guideline, specifc recommendations and suggestions have been presented for adults and subgroups like older people or those with cardiovascular disease, diabetes mellitus, chronic kidney disease, and COVID-19.

참고문헌 (102)

  1. Bastian H, "how will we ever keep up?", PLoS Med, 7(9), pp.e1000326~ (2010)
  2. García LM, "Guideline on terminology and definitions of updating clinical guidelines : the updating glossary", J Clin Epidemiol, 95, pp.28~33 (2018)
  3. Steinberg E, "Clinical practice guidelines we can trust" (2011), National Academies Press
  4. Alderson LJ, "Median life span of a cohort of National Institute for Health and Care Excellence clinical guidelines was about 60 months", J Clin Epidemiol, 67(1), pp.52~55 (2014)
  5. Martínez García L, "Strategies for monitoring and updating clinical practice guidelines : a systematic review", Implement Sci, 7, pp.1~10 (2012)
  6. Alonso-Coello P, "The updating of clinical practice guidelines : insights from an international survey", Implement Sci, 6, pp.1~8 (2011)
  7. Lyratzopoulos G, "Updating clinical practice recommendations : is it worthwhile and when?", Int J Technol Assess Health Care, 28(1), pp.29~35 (2012)
  8. Sarrafzadegan N, "Priority setting in cardiovascular research in Iran using standard indigenous methods", J Res Med Sci, 27(1), pp.91~ (2022)[DOI]
  9. Ogedegbe G, "Barriers to optimal hypertension control", J Clin Hyperten, 10(8), pp.644~646 (2008)
  10. Whelton P, "Acc", aha, abc, pp.acpm, ags[DOI]
  11. Williams B, "2018 ESC", ESH Guidelines for the management of arterial hypertension : The Task Force for the management of arterial hypertension of the European Society of Cardiology(ESC)and the European Society of Hypertension(ESH), 2018, pp.39(33), 3021~3104
  12. Leung AA, "Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension", Can J Cardiol, 32(5), pp.569~588 (2016)
  13. Corr L, "NICE guideline : the diagnosis and management of hypertension", Trends Urol Men’s Health, 10(6), pp.10~14 (2019)
  14. Noohi F, "The first Iranian recommendations on prevention, evaluation and management of high blood pressure", ARYA Atherosclerosis, 8(3), pp.97~ (2012)
  15. Collaboration PS, "Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies", Lancet, 360(9349), pp.1903~1913 (2002)
  16. Zhang Y, "Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample : the Strong Heart Study", Hypertension, 47(3), pp.410~414 (2006)
  17. Shahaj O, "Supporting self-management for people with hypertension : a meta-review of quantitative and qualitative systematic reviews", J Hypertens, 37(2), pp.264~279 (2019)
  18. Bress AP, "Cost-effectiveness of intensive versus standard blood-pressure control", N Engl J Med, 377(8), pp.745~755 (2017)
  19. "Guideline NG136 N. Hypertension in adults: diagnosis and management" (2023), National Institute for Health and Care Excellence (NICE)
  20. Canoy D, "How much lowering of blood pressure is required to prevent Cardiovascular Disease in patients with and without previous cardiovascular disease?", Curr Cardiol Rep, 24(7), pp.851~860 (2022)
  21. Jung M-H, "Age-specific associations between systolic blood pressure and cardiovascular mortality", Heart, 105(14), pp.1070~1077 (2019)
  22. Fuchs FD, "High blood pressure and cardiovascular disease", Hypertension, 75(2), pp.285~292 (2020)
  23. Afsargharehbagh R, "Hypertension and pre-hypertension among Iranian adults population : a meta-analysis of prevalence, awareness, treatment, and control", Curr Hypertens Rep, 21, pp.1~13 (2019)
  24. Shirani S, "Awareness, treatment and control of hypertension, dyslipidaemia and diabetes mellitus in an Iranian population : the IHHP study", EMHJ-East Mediter Health J, 15(6), pp.1455~1463 (2009)
  25. Lindsay P, "Recommendations on screening for high blood pressure in Canadian adults", Can Fam Phys, 59(9), pp.927~933 (2013)
  26. Commodore-Mensah Y, "Associations between social determinants and hypertension, stage 2 hypertension, and controlled blood pressure among men and women in the United States", Am J Hypertens, 34(7), pp.707~717 (2021)
  27. Davidson KW, "Developing primary care–based recommendations for social determinants of health : methods of the US Preventive Services Task Force", Ann Intern Med, 173(6), pp.461~467 (2020)
  28. Kirkland EB, "Trends in healthcare expenditures among US adults with hypertension : national estimates, 2003–2014", J Am Heart Assoc, 7(11), pp.e008731~ (2018)
  29. "Success Story: FQHC Relies on empowered care teams for underserved populations", Esperanza Health Centers, ~ (2019)
  30. Qualitative evaluation report of values, preferences and views of general practitioners regarding the problems of hypertensive patients, , ~ (2021)
  31. Arguedas JA, "Blood pressure targets in adults with hypertension", Cochr Database Syst Rev, (12), pp.CD004349~ (2020)[DOI]
  32. Garrison SR, "Blood pressure targets for hypertension in older adults", Cochrane Database Syst Rev, (8), pp.CD011575~ (2017)[DOI]
  33. Murad MH, "Antihypertensive agents in older adults : a systematic review and meta-analysis of randomized clinical trials", J Clin Endocrinol Metab, 104(5), pp.1575~1584 (2019)
  34. Saiz LC, "Blood pressure targets for the treatment of people with hypertension and cardiovascular disease", Cochrane Database Syst Rev, (11), pp.CD010315~ (2022)[DOI]
  35. Group SR, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373(22), pp.2103~2116 (2015)
  36. Howard K, "Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease : a modeled analysis", Value Health, 13(2), pp.196~208 (2010)
  37. Unger T, "2020 International Society of Hypertension global hypertension practice guidelines", Hypertension, 75(6), pp.1334~1357 (2020)
  38. Ashwell M, "Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors : systematic review and meta-analysis", Obes Rev, 13(3), pp.275~286 (2012)
  39. Neter JE, "Influence of weight reduction on blood pressure : a meta-analysis of randomized controlled trials", Hypertension, 42(5), pp.878~884 (2003)
  40. Jin A, "Effect of salt reduction interventions in lowering blood pressure in Chinese populations : a systematic review and meta-analysis of randomised controlled trials", BMJ open, 10, pp.e032941~ (2020)[DOI]
  41. He FJ, "Effect of longer term modest salt reduction on blood pressure : Cochrane systematic review and meta-analysis of randomised trials", BMJ, 346, pp.f1325~ (2013)[DOI]
  42. Kastorini C-M, "The effect of Mediterranean diet on metabolic syndrome and its components : a meta-analysis of 50 studies and 534, 906 individuals", J Am Coll Cardiol, 57(11), pp.1299~1313 (2011)
  43. Polito MD, "Resistance training to reduce resting blood pressure and increase muscle strength in users and non-users of anti-hypertensive medication : a meta-analysis", Clin Exp Hypertens, 43(5), pp.474~485 (2021)
  44. Zhong D, "Tai Chi for essential hypertension : a systematic review of randomized controlled trials", Curr Hypertens Rep, 22, pp.1~12 (2020)
  45. Ohta Y, "Effects of cigarette smoking on ambulatory blood pressure, heart rate, and heart rate variability in treated hypertensive patients", Clin Exp Hypertens, 38(6), pp.510~513 (2016)
  46. Xin X, "Effects of alcohol reduction on blood pressure : a meta-analysis of randomized controlled trials", Hypertension, 38(5), pp.1112~1117 (2001)
  47. Acin MT, "Alcohol intake reduction for controlling hypertension", Cochr Database Syst Rev, 2012(9), pp.CD010022~ (2020)[DOI]
  48. Cappuccio FP, "Blood pressure control by home monitoring : meta-analysis of randomised trials", BMJ, 329(7458), pp.145~ (2004)
  49. Qualitative evaluation report of values and preferences of HTN patients, , Development and Adapting Guidelines Department, ~ (2021)
  50. Sutton L, "Evidence for cost-effectiveness of lifestyle primary preventions for cardiovascular disease in the Asia-Pacific Region : a systematic review", Glob Health, 10(1), pp.1~19 (2014)
  51. Rahimi K, "Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure : an individual participant-level data meta-analysis", The Lancet, 397(10285), pp.1625~1636 (2021)
  52. Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387(10022), pp.957~967 (2016)
  53. Rahimi K, "Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death : an individual participant-level data meta-analysis", Lancet, 398(10305), pp.1053~1064 (2021)
  54. Zhong X-L, "Role of blood pressure management in stroke prevention : a systematic review and network meta-analysis of 93 randomized controlled trials", J Stroke, 23(1), pp.1~11 (2021)
  55. Takami Y, "Target blood pressure level for the treatment of elderly hypertensive patients : a systematic review and meta-analysis of randomized trials", Hypertens Res, 42(5), pp.660~668 (2019)
  56. Emdin CA, "Blood pressure lowering in type 2 diabetes : a systematic review and meta-analysis", JAMA, 313(6), pp.603~615 (2015)
  57. Wang S, "Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg : a meta-analysis", J Clin Hypertension, 21(2), pp.220~229 (2019)
  58. Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes : updated systematic review and meta-analysis", Lancet, 387(10017), pp.435~443 (2016)
  59. Asayama K, "Cardiovascular risk and blood pressure lowering treatment among elderly individuals : Evidence for cardiovascular prevention from observational cohorts in Japan", J Hypertens, 36(2), pp.410~418 (2018)
  60. Johnson R, "Shared decision making in consultations for hypertension : Qualitative study in general practice", Health Expect, 24(3), pp.917~929 (2021)
  61. Kisigo GA, "Understanding barriers and facilitators to clinic attendance and medication adherence among adults with hypertensive urgency in Tanzania", PLOS Global Public Health, 2(8), pp.e0000919~ (2022)
  62. Mancia G, "2007 Guidelines for the management of arterial hypertension : The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)", Eur Heart J, 28(12), pp.1462~1536 (2007)
  63. Meiqari L, "Access to hypertension care and services in primary health-care settings in Vietnam : a systematic narrative review of existing literature", Global Health Action, 12(1), pp.1610253~ (2019)
  64. Seeley A, "Pharmacotherapy for hypertension in Sub-Saharan Africa : a systematic review and network meta-analysis", BMC Med, 18, pp.1~11 (2020)
  65. Zhu J, "Calcium channel blockers versus other classes of drugs for hypertension", Cochr Database Syst Rev, (10), pp.1~80 (2021)
  66. den Brok MG, "Antihypertensive medication classes and the risk of dementia : a systematic review and network meta-analysis", J Am Med Directors Assoc, 22(7), pp.1386~1395 (2021)
  67. Chung EYM, "Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease", Cochrane Database Syst Rev, (10), pp.CD007004~ (2020)[DOI]
  68. Wright JT, "Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril", JAMA, 293(13), pp.1595~1608 (2005)
  69. Sareli P, "Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects : results of a randomized trial in Johannesburg, South Africa", Arch Inter Med, 161(7), pp.965~971 (2001)
  70. Mancia G, "2013 ESH", ESC Guidelines for the management of arterial hypertension, 2013, pp.17(2), 69~168
  71. Julius S, "VALUE trial : Long-term blood pressure trends in 13, 449 patients with hypertension and high cardiovascular risk", Am J Hypertens, 16(7), pp.544~548 (2003)
  72. Nissen SE, "Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure : the CAMELOT study : a randomized controlled trial", JAMA, 292(18), pp.2217~2225 (2004)
  73. Moran AE, "Cost-effectiveness of hypertension therapy according to 2014 guidelines", N Engl J Med, 372(5), pp.447~455 (2015)
  74. Faria C, "A narrative review of clinical inertia : focus on hypertension", J Am Soc Hypertens, 3(4), pp.267~276 (2009)
  75. Okonofua EC, "Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals", Hypertension, 47(3), pp.345~351 (2006)
  76. Salam A, "Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension : a systematic review and meta-analysis of randomized controlled trials", J Hypertens, 37(9), pp.1768~1774 (2019)
  77. Garjón J, "First-line combination therapy versus first-line monotherapy for primary hypertension", Cochrane Database Syst Rev, (2), pp.CD010316~ (2020)[DOI]
  78. Kwon A, "Single-pill combination therapy of Azilsartan Medoxomil", Chlorthalidone for treatment of hypertension : a systematic review, 2020, pp.42(7), 1390~1403
  79. Rea F, "Initial antihypertensive treatment strategies and therapeutic inertia : evidence from a large population-based cohort", Hypertension, 72(4), pp.846~853 (2018)
  80. Krousel-Wood M, "Medication adherence : a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients", Curr Opin Cardiol, 19(4), pp.357~362 (2004)
  81. Sherrill B, "Single-pill vs free-equivalent combination therapies for hypertension : a meta-analysis of health care costs and adherence", J Clin Hypertens, 13(12), pp.898~909 (2011)
  82. Birtwhistle RV, "Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners", BMJ, 328(7433), pp.204~ (2004)
  83. Ambrosius WT, "The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure : the Systolic Blood Pressure Intervention Trial(SPRINT)", Clin Trials, 11(5), pp.532~546 (2014)
  84. Cushman WC, "Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes(ACCORD)trial", Am J Cardiol, 99(12), pp.S44~S55 (2007)
  85. Walker RC, "Patient expectations and experiences of remote monitoring for chronic diseases : systematic review and thematic synthesis of qualitative studies", Int J Med Informatics, 124, pp.78~85 (2019)
  86. Organization WH, "Guideline for the pharmacological treatment of hypertension in adults", World Health Organization, ~ (2021)
  87. Xu W, "Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension : population based retrospective cohort study", BMJ, 350, pp.h158~ (2015)[DOI]
  88. Fragasso G, "Pathophysiologic therapeutic targets in hypertension : a cardiological point of view", Expert Opin Ther Targets, 16(2), pp.179~193 (2012)
  89. Golicki D, "Self-assessed health status in Poland : EQ-5D findings from the Polish valuation study", Pol Arch Med Wewn, 120(7–8), pp.276~281 (2010)
  90. Burke LE, "Current science on consumer use of mobile health for cardiovascular disease prevention : a scientific statement from the American Heart Association", Circulation, 132(12), pp.1157~1213 (2015)
  91. Gao W, "Telemedicine interventions to reduce blood pressure in a chronic disease population : A meta-analysis", J Telemed Telecare, 28(9), pp.621~631 (2022)
  92. Ma Y, "The effectiveness of electronic health interventions on blood pressure control, self-care behavioural outcomes and psychosocial well-being in patients with hypertension : A systematic review and meta-analysis", Int J Nurs Stud, 92, pp.27~46 (2019)
  93. Omboni S, "Clinical usefulness and cost effectiveness of home blood pressure telemonitoring : meta-analysis of randomized controlled studies", J Hypertens, 31(3), pp.455~468 (2013)
  94. Verberk WJ, "Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis", Blood Press Monit, 16(3), pp.149~155 (2011)
  95. Agarwal R, "Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control : a systematic review and meta-analysis", Hypertension, 57(1), pp.29~38 (2011)
  96. Liu S, "Reducing blood pressure with Internet-based interventions : a meta-analysis", Can J Cardiol, 29(5), pp.613~621 (2013)
  97. Walsh JM, "Quality improvement strategies for hypertension management : a systematic review", Med Care, 44(7), pp.646~657 (2006)
  98. Go AS, "An effective approach to high blood pressure control : a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention", Hypertension, 63(4), pp.878~885 (2014)
  99. Van Dyk L, "A review of telehealth service implementation frameworks", Int J Environ Res Public Health, 11(2), pp.1279~1298 (2014)
  100. Coorey GM, "Effectiveness, acceptability and usefulness of mobile applications for cardiovascular disease self-management : Systematic review with meta-synthesis of quantitative and qualitative data", Eur J Prev Cardiol, 25(5), pp.505~521 (2018)
  101. Whitehead L, "The effectiveness of self-management mobile phone and tablet apps in long-term condition management : a systematic review", J Med Internet Res, 18(5), pp.e97~ (2016)
  102. Blok S, "Success factors in high-effect, low-cost eHealth programs for patients with hypertension : a systematic review and meta-analysis", Eur J Prev Cardiol, 28(14), pp.1579~1587 (2021)

관련 논문AI추천

Highlights of the 2018 Chinese hypertension guidelinesLiu Jing대한고혈압학회 · Clinical Hypertension2020 · 제26권 제3호2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension김근호, 김현창, 박성하, 이장훈, 채성철, 편욱범, Hae-Young Lee, Jinho Shin, Ju Han Kim, Kwang-il Kim, Sang-Hyun Ihm대한고혈압학회 · Clinical Hypertension2019 · 제25권 제4호Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure박성하대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제1호고혈압의 진단 및 치료: 대한고혈압학회 진료지침을 기반으로안계택, 정진옥, 진선아대한신경과학회 · 대한신경과학회지2019 · 제37권 제2호The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension김광일, 김영권, 김주한, 김학령, 김현창, 박성하, 박종무, 신진호, 안신영, 이은미, 이장훈, 이해영, 조은주대한고혈압학회 · Clinical Hypertension2023 · 제29권 Intensive blood pressure control to prevent major cardiovascular events in individuals with high-normal blood pressure (prehypertension): PRINT-TAHA9 randomized clinical trialAbdollahi Ashkan, Attar Armin, Eskandarzadeh Parham, Mirhosseini Seyed Alireza, Sayadi Mehrab, Zibaeenezhad Mohammad javad대한고혈압학회 · Clinical Hypertension2026 · 제32권

이 간행물의 다른 논문 (35건)

Sex disparities in physical activity domains and hypertension prevalenceJung Yong Joon, 조민정, Jae Sae Young, Kim Hyun Jeong, Min Ho Jeong, Kunutsor Setor Kpp. 1-1Effect of low sodium and high potassium diet on lowering blood pressure and cardiovascular eventsYu Mi-yeon, Shin Jinho, 김병식pp. 2-2The association between body mass index and abdominal obesity with hypertension among South Asian population: findings from nationally representative surveysHaider Mohammad Rifat, Akonde Maxwell, Haider Shams Shabab, Pinky Susmita Dey, Pulock Orindom Shing, Kothadia Rohan Jay, Parray Ateeb Ahmad, Gupta Rajat Daspp. 3-3Elevated blood pressure among children born to women with obstructed labour in Eastern Uganda: a cohort studyWamulugwa Joan, Nahurira Doreck, Okello Dedan, Ssegawa Lawrence, Wandabwa Julius, Kiguli Sarah, Chebet Martin, Mukunya David, Musaba Milton W., Nambozo Brendah, Oguttu Faith, Makoko Brian Tonny, Napyo Agnes, Nantale Ritah, Wani Solomon, Tumuhamye Josephine, Auma Prossy, Atim Kettypp. 4-4The mediating effect of sleep disturbance on the association between hypertension and depression: a national data analysisLatief Kamaluddin, Sujarwadi Mokh, Hasan Faizul, Sithichoksakulchai Siriluk, Akyirem Samuel, Nurrika Dietapp. 5-5
원문 보기